# A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

> **NCT02469155** · PHASE3 · COMPLETED · sponsor: **Intra-Cellular Therapies, Inc.** · enrollment: 696 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ITI-007
- **DRUG:** Risperidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02469155
- **Lead sponsor:** Intra-Cellular Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 696 (ACTUAL)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02469155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02469155, "A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02469155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*